Coronary Stenting
Conditions
Keywords
ASA resistance, coronary stenting, platelet function, laboratory ASA resistance, MACE, Positive SPECT
Brief summary
The investigators prospectively studied the effect of aspirin on platelet function in 106 stable outpatients 6 months after successful percutaneous coronary angioplasty. Participants were randomized in a double-blind, double-crossover study (80 or 500 mg per day for 6 months).T
Detailed description
Background: Acetylsalicylic acid (aspirin) is widely used in the secondary prevention of coronary artery disease. There is controversy regarding the prevalence of aspirin resistance in patients with coronary artery disease and the effect of dose on resistance. Our primary aims were to determine the degree of platelet responsiveness to aspirin, and to study the influence of dose on platelet inhibition and clinical outcomes after coronary stenting.
Interventions
DRUG80 mg ASA dosing
DRUG500 mg ASA dosing
Sponsors
Shiraz University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 67 Years
Healthy volunteers
No
Inclusion criteria
* 6 months post stent without complication
Exclusion criteria
* subacute stent thrombosis * unable to discontinue plavix * dont accept to participate * contraindication for ASA use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| laboratory ASA resistance | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| major adverse cardiac events and positive cardiac scan for ischemia | 6 months |
Countries
Iran
Outcome results
None listed